TABLE 2

Effects of analogs on adrenal neurosecretion

Concentration-response effects of the analogs were determined as described under Materials and Methods; IC₅₀ values represent geometric means (confidence limits), n = 3 to 7.

Figure 1A			Figure 1B			Figure 1C			Figure 1D
Analog	Nicotine-Stimulated Neurosecretion (IC₅₀)	Analog	Nicotine-Stimulated Neurosecretion (IC₅₀)	Analog	Nicotine-Stimulated Neurosecretion (IC₅₀)	Analog	Nicotine-Stimulated Neurosecretion (IC₅₀)	Analog	Nicotine-Stimulated Neurosecretion (IC₅₀)
	μM		μM		μM		μM		μM
KAB 37	1.9 (1.6-2.2)	PPB 13	0.9 (0.8-1.1)	PPB 3	1.0 (0.9-1.2)	APB 3	2.1 (1.5-2.8)	APB12	13.0 (11-16)
KAB 36	2.0 (1.8-2.2)	KAB 20	1.3 (1.2-1.6)^a	PPB 5^b	1.2 (1.1-1.3)	APB 2	2.8 (2.5-3.1)	APB11	≥ 10
KAB 14	2.1 (1.9-2.4)	KAB 18	1.7 (1.6-1.8)^a	PPB 7	1.2 (1.1-1.3)	APB 8	2.8 (2.1-3.9)
KAB 16	2.5 (2.3-2.8)	KAB 21	3.0 (2.3-3.9)^a	IB 12	1.2 (1.2-1.3)	APB 9	4.0 (3.2-4.8)
KAB 17	2.7 (2.3-3.1)	KAB 23	3.2 (3.1-3.4)^a	IB 10^b	1.3 (1.1-1.4)^a	APB 6	6.6 (6.1-7.2)
KAB 11	2.8 (2.4-3.1)	KAB 24	3.2 (3.1-3.2)^a	IB 11	1.3 (0.7-2.4)^a	APB 5	7.1 (5.8-8.7)
KAB 35	3.3 (2.8-3.9)	KAB 22	3.4 (3.2-3.5)^a	JHB 1	1.3 (1.1-1.5)	APB 10	8.2 (6.2-9.8)
KAB 10	3.5 (3.5-3.6)	KAB 25	5.2 (4.8-5.6)^a	PPB 4	1.3 (1.2-1.3)	APB 4	≥ 10
KAB 38	3.5 (3.2-3.8)	KAB 31	6.0 (5.5-6.6)^a	IB 8	1.5 (1.5-1.5)^a	APB 1	≥ 10
KAB 12	3.7 (3.4-3.9)	KAB 30	7.5 (6.8-7.6)^a	PPB 6	1.6 (1.6-1.7)
KAB 33	4.2 (3.6-4.9)	KAB 19	8.4 (7.8-9.1)^a	PPB 1	1.7 (1.5-1.9)
KAB 13^b	4.4 (4.3-4.6)			IB 9	1.7 (1.7-1.7)^a
KAB 15	4.6 (4.0-5.3)			IB 7	2.5 (2.3-2.6)^a
KAB 29	5.3 (5.0-5.5)			PPB 11^b	2.6 (2.2-3.1)
KAB 8	5.4 (5.0-5.8)			IB 6	4.0 (3.7-4.3)^a
KAB 34^b	6.2 (5.3-7.2)			PPB 10	4.1 (3.8-4.5)
KAB 32	6.7 (6.0-7.5)			PPB 9	5.7 (5.0-6.5)
KAB 9	6.9 (6.5-7.3)			LB 5	65 (53-80)^c
LB 8	11 (10-12)^c			LB 4	114 (96-138)^c
IB 1	20 (19-21)^c
AB 2	27 (24-32)
LB 3	37 (28-48)^c
LB 7	52 (48-57)^c
LB 6^b	59 (55-63)^c
LB 1	63 (55-73)^c
LB 2	62 (59-66)^c

↵ a Data are from Bergmeier et al. (2004).
↵ b Test set compound.
↵ c Data are from Bryant et al. (2002).